Introduction
============

The collapse of the World Trade Center (WTC) on 9/11/2001 produced a massive exposure to dust and products of combustion \[[@B1]-[@B3]\]. The Fire Department of New York (FDNY) bureau of health services rapidly responded to this atrocity, initiating a medical monitoring program in October of 2001. Over 13,000 exposed rescue workers have been longitudinally followed by the FDNY-WTC-Medical Monitoring and Treatment Program. Approximately 7,000 exposed workers had serum samples drawn, stored and FEV~1~ and FVC measured within six months of 9/11/2001. A vast majority of those exposed had an acute decline in lung function in the first six months followed by stabilization. There was no recovery in lung function for the group as a whole, but a minority of those exposed recovered lung function over the following six and a half years.

We used serum obtained soon after the exposure to measure serum biomarkers of lung injury during the process of disease evolution. We reported that inflammatory cytokines, lipids and other measure of metabolic syndrome as well as biomarkers of cardiovascular risk predict abnormal lung function years later \[[@B4]-[@B6]\].

The balance of increased protease activity and reduced anti-protease activity are components of many diseases including cigarette-induced chronic lung disease and other causes of accelerated lung function decline \[[@B7]-[@B10]\]. Genetic association studies with matrix metalloproteinases (MMPs) demonstrate a strong association with the development of lung disease \[[@B7]\]. MMP-1 is induced in smokers with COPD and its overexpression in mice causes emphysema \[[@B11],[@B12]\]. The destructive effects of MMPs are inhibited by tissue inhibitors of matrix metalloproteinases (TIMPs). Since most clinical investigation focuses on disease, there is little data on the role of MMPs and TIMPs in the resistance to the damaging effect of dust exposure \[[@B13]-[@B16]\]. One carefully done pathologic study demonstrated increased MMP-2 and TIMP-1 mRNA expression in surgically removed lung and predicted improved FEV~1~ in COPD patients \[[@B17]\]. Serum MMP and TIMP expression reflects the severity of COPD supporting an investigation of a link between serum MMP/TIMP balance and lung function in the WTC exposed cohort \[[@B18]\].

This study investigates serum expression of MMPs and TIMPs soon after damaging particulate matter exposure and tests if protease/anti-protease balance is associated with a subgroup that demonstrates an above average healing potential after WTC-LI. We report that elevated TIMP-1 and MMP-2 predicts recovery of lung function while elevated MMP-1 reduces the odds of recovery years after WTC exposure.

Methods
=======

Study participants and design
-----------------------------

The Institutional Review Boards (IRB) of NYU and Montefiore Medical Center approved this study and patients signed consent at the time of serum draw within 6 months of 9/11/2001 (Montefiore Medical Center IRB; \#07-09-320 and New York University IRB; \#11-00439). The parent cohort for this investigation consists of 1,720 exposed workers who required subspecialty pulmonary examination (SPE) prior to 3/10/2008.

A nested case--control study tested the association of serum biomarkers and FEV~1~ at SPE. The baseline cohort N = 801 was assembled to exclude patients with abnormal pre-9/11 FEV~1~ and tobacco use to eliminate these confounders of post exposure lung function \[[@B19]\]. Resistant cases (N = 100/801) had a FEV~1~% one standard deviation above the mean (\>107%) at SPE. Controls (N = 171/801) were randomly selected after stratification of the baseline cohort for BMI and FEV~1~. Serum was available for N = 137/171 of the cohort controls, N = 77/100 of the resistant cases. For this case--control study, the control subjects are all individuals in the random sample cohort control who did not meet criteria to be resistant cases. Analyte distribution in the cohort controls identified the 75^th^ percentile cut points used to define elevated biomarker expression.

Serum biomarker assays
----------------------

Processing of blood has been previously described \[[@B6],[@B20]\]. Biomarkers were assayed with a TIMP panel (R&D Systems, Minneapolis, MN), and MMP panel (Procarta/Affymetrix) using a Luminex 200-IS (Luminex Corporation, Austin, TX). Each plate contained 1:2 ratio of resistant cases to controls to account for batch effect.

### Chest computed tomography (CT)

We have reported on lung function and computed tomography (CT) findings of this group. High-resolution chest CT scans were obtained with 7-mm thick mages reconstructed at 6-mm intervals. Images were read for airway and parenchymal abnormalities by dedicated, board certified radiologists who had no knowledge of the subjects' exposure status or clinical findings. Bronchial wall thickening and air-trapping were interpreted qualitatively and analyzed as a yes/no variable.

Statistical analysis
--------------------

Database management and statistics used SPSS 20 (IBM, Armonk, NY). Odd ratios were modeled with multivariate binary logistic regression with case status as the outcome. Analyte cutoff values were the 75^th^ percentile cohort control expression. The Hosmer-Lemeshow goodness-of-fit test was used to assess calibration of the final model. The model discrimination was evaluated using the receiver operating characteristic area under the curve (AUC).

Results
=======

Participants
------------

Derivation of cases and controls is depicted in Figure  [1](#F1){ref-type="fig"}. N = 111/171 cohort controls with serum available for study were compared to N = 77/100 resistant cases. Controls were not significantly different from the baseline cohort in arrival time, years of service, age, time to all pulmonary examinations, or BMI, Table  [1](#T1){ref-type="table"}. Controls had higher BMI than resistant cases. Time to medical monitoring entry (MME), when spirometry was performed and serum drawn, was 2 months in cases and controls. Time to subspecialty pulmonary evaluation SPE, when spirometry that defined case status was performed, was 32 months in cases and controls.

![**Study design.** Derivation of cases n = 77 and controls n = 111 from the FDNY-MMTP.](1465-9921-15-5-1){#F1}

###### 

Demographics

                        **Date/event**   **Baseline cohort**   **Sub-cohort controls**   **Resistant cases**   **p**
  --------------------- ---------------- --------------------- ------------------------- --------------------- -------
  WTC Exposure, n(%)    High             197 (25)              21 (19)                   14 (18)               1.000
                        Intermediate     604 (75)              90 (81)                   63 (82)                
  9/11 to PFT, months   MME              2.7 (2.0-3.8)         2.5 (2.0-3.2)             2.6 (2.2-3.2)         0.219
                        SPE              33.8 (24.8-57.0)      32.7 (24.6-57.4)          32.5 (28.3-52.2)      0.755
  BMI, kg/m2            MME              28.0 (26--30)         28.1 (26--31)             27.3 (26--29)         0.018
                        SPE              28.9 (27--31)         29.1 (27--31)             27.6 (26--30)         0.010
  Years of service      9/11/01          13 (7--19)            14 (7--18)                14 (10--19)           0.249
  Age                   9/11/01          40 (36--45)           41 (36--44)               42 (38--46)           0.159

*WTC* World trade center, *PFT* Pulmonary function test, *BMI* Body mass index, *MME* Medical monitoring entry, *SPE* Subspecialty pulmonary exam.

Expressed as median (interquartile range.

Longitudinal lung function in resistant cases and controls
----------------------------------------------------------

Cases and controls underwent three longitudinal measures of lung function. The first spirometry documented pre-exposure lung function; the second was immediately after exposure at MME and the third was later at SPE, Table  [2](#T2){ref-type="table"} and Figure  [2](#F2){ref-type="fig"}. Resistant cases had higher median pre-9/11 FEV~1~ than controls (117% vs 98% p \< 0.001).

###### 

Longitudinal lung function assessment of cohort

  **Time**   **Variable**                  **Controls**       **Resistant**     **p**
  ---------- ----------------------------- ------------------ ----------------- ----------
  Pre-9/11   FEV1%                         98 (90--108)       117(108--124)     \<0.0001
             FEV1/FVC                      84 (81--87)        87 (84--89)       \<0.0001
  MME        FEV1%                         91 (81--96)        105(97--113)      \<0.0001
             FEV1/FVC                      84 (79--87)        85 (83--89)       \<0.0001
  SPE        FEV1%                         93 (83--98)        113 (109--119)    \<0.0001
             FEV1/FVC                      77 (73--79)        81 (79--84)       \<0.0001
             BD response                   5 (2--10)          5(2--9)           0.776
             BD response \> 12%, N (%)     13/46 (28)         5/23 (22)         0.772
             MCT slope                     0.64 (0.31-0.15)   0.04(0.02-0.07)   0.010
             PC20 \< 10 mg/mL MCT, N (%)   17/86 (20)         6/66 (9)          0.108
             TLC                           103 (95--109)      106 (103--116)    0.016
             RV,% Pred                     125 (113--141)     111 (103--123)    0.015
             DLCO                          106 (99--114)      116 (108--131)    0.001
             VA                            93 (85--98)        100 (95--105)     \<0.0001
             DLCO/VA                       120 (107--130)     110 (107--126)    0.358

*FEV1* Forced expiratory volume in one second, *FVC* Forced vital capacity, *MCT* Methacholine, *BD* Bronchodilator, *PC20* concentration of methacholine causing a 20% fall in FEV1, *DLCO* Diffusion capacity of the lung for carbon monoxide, *VA* Alveolar volume.

![**FEV**~**1**~**% predicted of cases and controls over time.** Mean (SD) expressed for cases n = 77 (green) and controls n = 111 (grey) at Pre-9/11, MME and SPE.](1465-9921-15-5-2){#F2}

FEV~1~ declined in cases and controls soon after exposure. To test if group data represented individuals' response the ratio of FEV~1~ pre-9/11 to FEV~1~ at MME was calculated for each case and controls. The mean (SD) of MME/Pre-911 ratio was 0.91(0.10) for resistant cases and 0.91 (0.12) for controls (p = 0.95 for cases vs control). Cases recovered most of the lost FEV~1~ (117% to 113%). Controls had less improvement than cases in their median FEV~1~ (98% to 93%). To test if group data represented individuals' response the ratio of FEV~1~ pre-9/11 to FEV~1~ at SPE was calculated for each case and controls. The SPE/Pre-911 ratio was 0.99+/-0.09 for resistant cases and 0.91+/-0.12 for controls (p \< 0.001 for cases vs control). Raw FEV~1~% predicted has also been shown in Figure  [2](#F2){ref-type="fig"}.

Both groups had a decline in FEV~1~/FVC ratio SPE/MME, with resistant cases having the less than controls (0.85 to 0.81 p \< 0.001). Both cases and controls had a high proportion of individuals with bronchodilator response (22% vs 28% NS). Cases had less methacholine reactivity when measured as a continuous slope (0.64 vs 0.04 p \< 0.01); 9% of cases reactive to a 10 mg/ml dose while 20% of controls were reactive (p = 0.11). Cases had less air trapping than controls (111% vs 121% p \< 0.02) when residual volume was used to measure air trapping Table  [3](#T3){ref-type="table"}. At SPE, resistant cases had the higher TLC, DLCO and alveolar volume than controls (p \< 0.001 for all comparisons), Table  [2](#T2){ref-type="table"}.

###### 

Chest CT abnormalities in cases and controls

  **CT Finding**              **Controls**   **Resistant cases**   **p†**
  --------------------------- -------------- --------------------- --------
  Bronchial wall thickening   23/65 (35)     5/36 (14)             0.022
  Air trapping                30/65 (46)     10/36 (28)            0.090
  Nodules                     25/65 (38)     13/36 (36)            0.834

^†^Significance calculated by Chi-Squared.

Chest CT of resistant cases and controls
----------------------------------------

Chest imaging was used to investigate if resistant cases and controls had structural differences. In those with chest CT images available, 14% of the resistant cases had bronchial wall thickening whereas 35% of the controls had this evidence of airway inflammation (p \< 0.03), Table  [3](#T3){ref-type="table"}. There was no significant difference between cases and controls in air trapping defined by mosaic attenuation (28% vs 46% p = 0.09). Both cases and controls have a high proportion of pulmonary nodules (38% vs 36% p = 0.8).

Biomarker models
----------------

Analyte levels were compared between controls and resistant cases, Table  [4](#T4){ref-type="table"}. We used logistic regression with analyte expression above a pre-defined 75^th^ percentile cut points to test if protease or anti-proteases expression predicted resistance to WTC-LI \[[@B21]\]. Models were adjusted for BMI, age, exposure group and pre-9/11 FEV~1~. Reduced models examined the ability of a single analyte to predict each case definition. Analytes with significant odds ratios in single biomarker models were used to develop the final multi-analyte model.

###### 

Serum biomarkers

                   **Analyte pg/mL**   **75th percentile cutpiont**   **Controls**              **Resistant**            **OR (95% CI)**                                 
  ---------------- ------------------- ------------------------------ ------------------------- ------------------------ ------------------------- --------------------- ---------------------
  Proteases        MMP-1               1239                           689 (264--1210)           27/111                   549 (233--1013)           14/77                  0.691 (0.335-1.425)
  MMP-2            4949                2933 (1570.01-4608.25)         22/111                    3340 (2108.19-5682.13)   27/77                     2.185 (1.128-4.231)   
  MMP-3            13345               7494 (2940--13358)             28/111                    6906 (3457--11509)       17/77                     0.840 (0.422-1.671)   
  MMP-7            355                 217 (100--333)                 25/111                    237 (95--375)            22/77                     1.376 (0.707-2.-77)   
  MMP-8            157                 10 (10--156)                   27/111                    10 (10--116)             16/77                     0.816 (0.405-1.645)   
  MMP-9            62086               22559 (10596--40806)           24/111                    23003 (12043--64398)     21/77                     1.359 (0.692-2.670)   
  MMP-12           306                 66 (18--306)                   28/111                    55 (27--277)             19/77                     0.971 (0.496-1.902)   
  MMP-13           138                 75 (10--133)                   26/111                    71 (10--140)             20/77                     1.147 (0.585-2.248)   
  Anti-proteases   TIMP-1              155003                         125491 (100396--151151)   23/111                   126292 (100483--164661)   29/77                  2.312 (1.206-4.430)
  TIMP-2           115905              102470 (89901--113738)         23/111                    103199 (88959--119820)   22/77                     1.530 (0.780-3.005)   
  TIMP-3           31922               7750 (7750--31922)             29/111                    7750 (7750--33680)       21/77                     1.060 (0.550-2.044)   
                   TIMP-4              1585                           1242 (9288--1562)         26/111                   1342 (970-(1717)          27/77                  1.765 (0.929-3.354)

*MMP* matrix metalloproteinase, *TIMP* Tissue inhibitor of matrix metalloproteinase, *OR* Odds RATIO (unadjusted), *IQR* Interquartile range.

Using 75^th^ percentile of cohort expression, we calculated OR with FEV1 \> 107% at SPE as the outcome. Elevated MMP-1 reduces the odds of FEV1 \> 107% by 31%, elevated MMP-2 increases the odds of FEV1 \> 107% by 218% and elevated TIMP-1 increases the odds by 231%. After adjusting for BMI, age, exposure group and pre-9/11 FEV~1~ elevated MMP-1 reduces the odds of resistance to WTC-LI by 68% while individuals with high MMP-2 and TIMP-1 were 300% and 350% more likely to resist WTC-LI, Table  [4](#T4){ref-type="table"}. Combining MMP-1, MMP-2 and TIMP-1 in a multi-analyte model improved the OR for each of these biomarkers, Table  [5](#T5){ref-type="table"}. Elevated MMP-1 was a risk factor reducing the odds of resistance to lung injury to 0.27 (95% CI 0.09-0.82 p = 0.02). Elevated MMP-2 and TIMP-1 were protective factors improving odds of resistance by 4.2 fold (95% CI 1.6-10.8 p = 0.003) and 5.4 fold (95% CI 1.9-14.9 p = 0.001), Table  [5](#T5){ref-type="table"}. The area under the receiver operator curve for the multi-analyte model was 0.90 (95% CI; 0.86-0.94). (Figure  [3](#F3){ref-type="fig"}) The sensitivity and specificity of the model was 74% and 86% respectively.

###### 

Model of resistance to WTC-lung injury

                    **Serum biomarker**     **OR (95% CI)**
  ----------------- --------------------- -------------------
  Single analyte    MMP-1 ≥ 1239           0.33 (0.11-0.93)
  MMP-2 ≥ 4949      3.00 (1.25-7.18)      
  TIMP-1 ≥ 155003   3.52 (1.41-8.81)      
  Multi-analyte     MMP-1 ≥ 1239           0.27 (0.09-0.82)
  MMP-2 ≥ 4949      4.16 (1.61-10.76)     
                    TIMP-1 ≥ 155003        5.38 (1.94-14.94)

§Models Adjusted for: BMI at SPE, exposure Group, Age at 9/11 and Pre-9/11 FEV~1~% Predicted; -2 Log Likelihood 144.081; Hosmer and Lemeshow (Goodness of Fit) Sig 0.743.

![**Receiver operator characteristics (ROC) of final multi-analyte model.** Area Under the Curve (AUC) = 0.901: 95% CI (0.860-0.943).](1465-9921-15-5-3){#F3}

Discussion
==========

We report that elevated MMP-1, MMP-2 and TIMP-1 in serum shortly after WTC exposure predicts subsequent return of FEV~1~ to pre-exposure values. All subjects in this nested case control investigation had significant WTC dust exposure, arriving at the collapse site within 2 days of 9/11/2001. The FDNY measured serial FEV~1~ pre and post 9/11. We focused our current study on a subgroup of highly exposed individuals who did not suffer persistent FEV~1~ decline. This resistant subgroup had greater than average reduction in FEV~1~ immediately after exposure but returned to pre-exposure FEV~1~ over the next 6.5 years. Because serum was drawn well before the pulmonary function test that demonstrated recovery, the biomarker information reflected the evolving response to injury. MMP-2 and TIMP-1 expression above the 75^th^ percentile are protective biomarkers, significantly increasing the odds of resistance between 4.2 and 5.4 fold. Alternately, elevated MMP-1 is a risk factor, reducing the odds of resistance by 73%. The biomarker model using serum MMP-1, MMP-2 and TIMP-1 concentration predicted resistance with a sensitivity of 74%, a specificity of 86% and a receiver operator characteristic of 0.90.

As expected in this highly exposed group, both cases and controls suffered an acute reduction in FEV~1~ as a result of WTC exposure. Resistant cases differed from controls because they returned to 99% of their pre-exposure FEV~1~. Over the 6.5 years post 9/11 FEV~1~ returned to only 91% of their pre-exposure FEV~1~. The return of FEV~1~ to pre-exposure levels provides evidence that resistant cases have above average capacity to heal after an acute injury.

Elevated TIMP-1 and MMP-2 expression increases the odds of being resistant 4.1 and 5.3 fold respectively. These results remain significant after adjusting for multiple comparisons. Although TIMP and MMP over expression have been observed in COPD and are probably affected by chronic injury secondary to cigarette smoke or other damaging processes, interpreting the cause and effect relationship between lung function and MMP/TIMP balance in humans has been challenging \[[@B22]-[@B24]\]. A carefully done study of 63 patients who had surgery for lung cancer or lung transplantation demonstrated that increasing TIMP-1 and MMP-2 mRNA in the small airways and/or the parenchyma surrounding the small airway was positively associated with FEV~1~\[[@B17]\]. Our findings on particulate matter induced lung injury are consistent with these findings in smoking related COPD patients. The mechanisms involved in the protective effects of TIMP-1 and MMP-2 in response to particulate matter induced lung injury require further study.

Since resistant cases were defined by a FEV~1~ of \> 107%, starting close to this threshold should increase the likelihood of crossing this defining value. After adjusting the logistic model for pre-9/11 FEV1, the association of MMP-1 MMP-2 and TIMP-1 with better than average post exposure FEV~1~ markedly improved as quantified by their ORs. This suggests that while pre-existing differences in lung function is a confounder including them in the regression allowed the biomarker-lung function association to remain robust. We briefly examined if excluding individuals who failed their MCT by the 3^rd^ level would alter our results. We found that the ORs of MMP-1, MMP-2 and TIMP-1 remained significant and of the same magnitude (data not shown). Furthermore, we repeated the analysis in a population with their Pre-9/11 FEV~1~% predicted constrained; cases n = 58 had an FEV~1~ of 96--146 and controls n = 58 had an FEV~1~ of 96--143. Using this constrained population OR (95% CI) were as follows: MMP-1 0.318 (0.098-1.039), MMP-2 4.993 (1.664-14.983) and TIMP-1 8.061 (2.423-26.825). Importantly, patients with resistance to WTC-LI had at subspecialty pulmonary evaluation increased TLC measured on plethysmography, increased alveolar volume measured by methane dilution and increased diffusion of carbon monoxide than controls. In animal models, MMP-2 is required for normal lung development and failure to produce MMP-2 leads to emphysema and collagen deposition around the bronchioles \[[@B25]-[@B27]\]. Our data is consistent with the hypothesis that MMP-2 and TIMP-1 are biomarkers of an individual's intrinsic capacity to heal after irritant induced lung injury.

The resistant cases also had significantly less bronchial wall thickening on chest CT. Accumulation of inflammatory cells in the bronchovascular bundle likely accounts for this radiographic finding \[[@B28]\]. Our Chest CT findings suggest that the resistant group accumulates fewer inflammatory cells around the bronchovascular bundle after dust exposure. Interestingly, in rodent models of lung injury, MMP-2 expression reduces bronchovascular inflammatory cells and enhances repair \[[@B29],[@B30]\]. Since the chest CT was performed years after the insult, the mechanism that produced the bronchial wall thickening persists for years after the original exposure that precipitated the inflammation.

Conversely, elevated MMP-1 reduced the odds of being resistant to WTC-LI to 0.27. This association, however, becomes insignificant when adjusted for multiple comparisons. We have maintained MMP-1 in the model because of the overwhelming evidence that this protease is an important is disease pathogenesis. Over expression of MMP-1 leads to emphysema in animal models \[[@B31]\]. In humans, MMP-1 is expressed in type II pneumocytes of patients with COPD but not controls \[[@B11],[@B12]\]. The 73% reduction in the odds of having above average FEV~1~ is consistent with the damaging effects of this protease on lung integrity.

Since we excluded ever smokers and individuals with pre-9/11 lung disease, our results are not confounded by these common causes of FEV~1~ decline that are unrelated to inhalation of WTC dust. Another advantage of this study is the SPE PFT was performed during the initial pulmonary evaluation prior to treatment initiation. Therefore our results are not confounded by treatment effect. In spite of our objective case definition, using FEV~1~ as a single measure did produce misclassification of disease. The resistant group with FEV~1~ \> 107% at SPE did have a individuals with evidence of airway injury. Up to 22% of the resistant cases had airway reactivity on PFT or radiographic evidence of bronchial wall thickening. This misclassification of disease should bias toward the null. In spite of this bias, we observed highly significant associations between biomarkers in serum drawn soon after exposure and above average lung function years later.

This nested case control study has several limitations. The cohort was highly unusual, suffering an acute overwhelming exposure to PM that overwhelmed normal protective mechanisms. The results therefore have limited generalizability. The findings require replication in independent particulate matter exposed cohorts. Even though the serum biomarkers were expressed years before the FEV~1~ that defined resistance to lung injury, the results are correlations and do not imply causation. It is possible that exposure lead to an alteration in these biomarkers due to different mechanisms controlling lung injury. Alternately, pre-existing attenuation of these biomarkers may lead to differential healing. Further, investigation in model systems and longitudinally followed cohorts is required to better understand the role, if any, of MMP-1 and TIMP-1 in healing after PM induced lung injury. Finally, this study had no unexposed control group because the few unexposed workers were markedly different from the exposed group with poor health that prevented them from working at the WTC collapse site. This restricts our ability to assess the impact of WTC exposure to the observed biomarker disease relationship.

This report documents the serum biomarkers that predict better than average FEV~1~ after massive dust exposure. This group had evidence of healing with return to pre-9/11 FEV~1~ after a significant drop immediately post exposure. The processes initiated by WTC exposure impacted multiple distinct injury and repair pathways. One interpretation of the findings is that biomarkers of resistance reflect biological processes leading to healing after particulate matter induced injury.
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